Volume : VII, Issue : IV, April - 2018
Bronchodilator reversibility in chronic obstructive pulmonary disease
Dr. Ajithkumar. C. S.
Abstract :
Background: Although airflow obstruction in COPD is not fully reversible, patients can still exhibit clinically significant onchodilator reversibility. This study assessed onchodilator reversibility in COPD
Materials and methods: Spirometric parameters were measured before and after inhaled 400 µg salbutamol. Responses were classified using the American Thoracic Society (ATS)/European Respiratory Society (ERS) criteria and patients were classified as reversible and irreversible.
Result: There was a clear positive correlation between FEV1 reversibility and FVC reversibility. FEV1 increased significantly with onchodilator in 25% of COPD patients, a response that was normally distributed. FVC reversibility was seen in 62.5% of COPD
Conclusion: COPD patients on the mild side of the severity spectrum differ from patients on the severe side regarding the association between their onchodilator flow and volume responses.
Keywords :
Article:
Download PDF
DOI : https://www.doi.org/10.36106/paripex
Cite This Article:
Dr. Ajithkumar. C. S., Bronchodilator reversibility in chronic obstructive pulmonary disease, PARIPEX‾INDIAN JOURNAL OF RESEARCH : Volume-7 | Issue-4 | April-2018
Number of Downloads : 403
References :
Dr. Ajithkumar. C. S., Bronchodilator reversibility in chronic obstructive pulmonary disease, PARIPEX‾INDIAN JOURNAL OF RESEARCH : Volume-7 | Issue-4 | April-2018